Androgens
Trenbolone
An anabolic androgen whose human harm data require careful separation from online performance claims.
Human research / important limitations
Also known as: Tren · trenbolone acetate · trenbolone enanthate
Practical use
Applying the explained evidence
- Where it fits
- An anabolic androgen whose human harm data require careful separation from online performance claims.
- Put the information into practice
- A survey cannot establish a safe exposure or predict an individual’s response. Concurrent substance use, selection and recall may affect the comparison. This study provides no reliable numerical forecast of physique gains.
- Formulation and purpose
- Write down the exact compound and formulation behind a claim. Compare the studied population and purpose with the situation being discussed; evidence for medical replacement does not automatically answer a physique-enhancement question.
- Keep this limit in view
- Observational, self-reported data. The groups were not randomized and the design cannot isolate causation or establish event rates for a standardized product.
Overview
Trenbolone is an anabolic-androgenic steroid. The human study summarized here investigates reported harms among people using steroids, rather than measuring muscle gain in a controlled treatment trial.
Risks and limitations
In the cited survey, people reporting trenbolone use also reported more mood-related and physical concerns. These are associations, not verified diagnoses or proof that trenbolone alone caused each problem.
How to read this
A survey cannot establish a safe exposure or predict an individual’s response. Concurrent substance use, selection and recall may affect the comparison. This study provides no reliable numerical forecast of physique gains.
Research explained
International survey of steroid users
Who was studied
1,146 men reporting past-year AAS use in Global Drug Survey 2024; 237 reported trenbolone and 909 did not.
What was found
Mood instability, irritability and depressive symptoms were more common in the trenbolone group (all P<.001; phi effect sizes 0.13–0.20). Cardiovascular and hepatic concerns were also more frequent (P<.001; phi 0.18–0.20). These are reports of concerns, not adjudicated disease diagnoses.
What it cannot establish
Observational, self-reported data. The groups were not randomized and the design cannot isolate causation or establish event rates for a standardized product.
Read the original studyAssociation, causation and precision
The survey compared 237 respondents reporting trenbolone with 909 reporting other AAS use. Exposure was not randomized, products were not standardized, and concurrent behavior may differ. The phi statistic describes association strength; 0.20 does not mean that 20% of users develop a condition.
Supporting sourceLearn with Avery
Trenbolone — The Complete Guide to Running Tren Correctly (Dose, Sides, Bloodwork, Protocols)
Sources
International survey of steroid users
Sources checked 2026-09-28.
General education; not a personal treatment plan.